{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:30:12Z","timestamp":1787985012641,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As a natural antioxidant, uric acid plays a protective role against neurodegenerative disorders, including Parkinson\u2019s disease (PD). Therefore, the risk of PD has been found to be lower in people with hyperuricemia. In this article, we conducted a systematic review and meta-analysis to investigate whether gout affects the future risk of developing PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed, Scopus, the Web of Science, and Google Scholar to find relevant studies, up to March 16, 2022. Studies investigating the risk of PD, following a gout diagnosis, were included if they were cross-sectional, case\u2013control or cohort studies. The Newcastle Ottawa Scale (NOS) checklist was used to assess the quality of all included studies. The meta-analysis was performed using STATA 17.0.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ten studies were included, which were comprised of three case-controls, six cohort studies and one nested case\u2013control study. We found no significant association between gout and the risk of PD among both sexes (RR\u2009=\u20090.94, 95% CI: 0.86\u20131.04), although the association was significant for females (RR\u2009=\u20091.09; 95% CI: 1.02\u20131.17). Subgroup analysis also showed no significant findings by age group, whether they were receiving treatment for gout, study design, quality assessment score, and method of gout ascertainment. In contrast, the studies that defined PD according to the use of drugs showed significant results (RR\u2009=\u20090.82; 95% CI: 0.76\u20130.89). There was a significant publication bias on the association between gout and PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The presence of gout had no significant effect on the risk of subsequently developing PD. Further analyses are recommended to investigate the effects of demographic and behavioral risk factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02874-0","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T05:02:44Z","timestamp":1665464564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Association between gout and the development of Parkinson\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Asra","family":"Fazlollahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Zahmatyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Noori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Aria","family":"Nejadghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J. M.","family":"Sullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koroush","family":"Gharagozli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali-Asghar","family":"Kolahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Safiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"2874_CR1","doi-asserted-by":"crossref","unstructured":"Duarte-Jurado AP, Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MD, Montes-de-Oca-Luna R, Garcia-Garcia A, et al. Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities. Antioxidants. 2021;10(3).","DOI":"10.3390\/antiox10030453"},{"issue":"8","key":"2874_CR2","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10072-019-03872-w","volume":"40","author":"P Eusebi","year":"2019","unstructured":"Eusebi P, Franchini D, De Giorgi M, Abraha I, Montedori A, Casucci P, et al. Incidence and prevalence of Parkinson\u2019s disease in the Italian region of Umbria: a population-based study using healthcare administrative databases. Neurol Sci. 2019;40(8):1709\u201312.","journal-title":"Neurol Sci"},{"issue":"7","key":"2874_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AH Schapira","year":"2017","unstructured":"Schapira AH, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350.","journal-title":"Nat Rev Neurosci"},{"key":"2874_CR4","unstructured":"De Rijk Md, Launer L, Berger K, Breteler M, Dartigues J, Baldereschi M, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S21\u20133."},{"issue":"S1","key":"2874_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1017\/S0317167100041457","volume":"19","author":"A Rajput","year":"1992","unstructured":"Rajput A. Frequency and cause of Parkinson\u2019s disease. Can J Neurol Sci. 1992;19(S1):103\u20137.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"2874_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mdc3.12568","volume":"5","author":"MM Abbas","year":"2018","unstructured":"Abbas MM, Xu ZY, Tan LC. Epidemiology of Parkinson\u2019s Disease-East Versus West. Movement Disorders Clinical Practice. 2018;5(1):14\u201328.","journal-title":"Movement Disorders Clinical Practice"},{"key":"2874_CR7","doi-asserted-by":"crossref","unstructured":"Gra\u017cy\u0144ska A, Adamczewska K, Antoniuk S, Bie\u0144 M, To\u015b M, Kufel J, et al. The Influence of Serum Uric Acid Level on Non-Motor Symptoms Occurrence and Severity in Patients with Idiopathic Parkinson's Disease and Atypical Parkinsonisms-A Systematic Review. Medicina (Kaunas). 2021;57(9).","DOI":"10.3390\/medicina57090972"},{"issue":"1","key":"2874_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol. 2011;26(1):1\u201358.","journal-title":"Eur J Epidemiol"},{"issue":"S3","key":"2874_CR9","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner P. Oxidative stress in Parkinson\u2019s disease. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2003;53(S3):S26\u201338.","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"issue":"7","key":"2874_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/antiox9070597","volume":"9","author":"KH Chang","year":"2020","unstructured":"Chang KH, Chen CM. The Role of Oxidative Stress in Parkinson\u2019s Disease. Antioxidants (Basel). 2020;9(7):597.","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"2874_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1994;36(3):348\u201355.","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"2874_CR12","doi-asserted-by":"crossref","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiology of Aging. 2003;24(2):197-211.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"2874_CR13","doi-asserted-by":"crossref","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nature Reviews Disease Primers. 2017;3(1):17013.","DOI":"10.1038\/nrdp.2017.13"},{"issue":"Pt B","key":"2874_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.expneurol.2017.06.017","volume":"298","author":"GF Crotty","year":"2017","unstructured":"Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017;298(Pt B):210\u201324.","journal-title":"Exp Neurol"},{"key":"2874_CR15","doi-asserted-by":"crossref","unstructured":"Dorsey Ea, Constantinescu R, Thompson J, Biglan K, Holloway R, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6.","DOI":"10.1212\/01.wnl.0000247740.47667.03"},{"key":"2874_CR16","doi-asserted-by":"crossref","unstructured":"Kalia L, Lang A. Parkinson\u2019s disease. Lancet Lond Engl. 2015;386:896\u2013912.","DOI":"10.1016\/S0140-6736(14)61393-3"},{"issue":"5","key":"2874_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jnc.12949","volume":"131","author":"I Martin","year":"2014","unstructured":"Martin I, Kim JW, Dawson VL, Dawson TM. LRRK2 pathobiology in Parkinson\u2019s disease. J Neurochem. 2014;131(5):554\u201365.","journal-title":"J Neurochem"},{"issue":"1","key":"2874_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10072-018-3585-x","volume":"40","author":"R Kaur","year":"2019","unstructured":"Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson\u2019s disease: pathophysiology to management. Neurol Sci. 2019;40(1):13\u201323.","journal-title":"Neurol Sci"},{"issue":"1\u201302","key":"2874_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.18071\/isz.75.0051","volume":"75","author":"BC Ari","year":"2022","unstructured":"Ari BC, Tur EK, Domac FM, Kenangil GO. Uric acid: The role in the pathophysiology and the prediction in the diagnosis of Parkinson\u2019s disease: A Turkish-based study. Ideggyogy Sz. 2022;75(1\u201302):51\u20139.","journal-title":"Ideggyogy Sz"},{"key":"2874_CR20","doi-asserted-by":"crossref","unstructured":"LANG AL A. Parkinson\u2019s disease. First of two parts. N Engl J Med. 1998;339(15):1044\u201353.","DOI":"10.1056\/NEJM199810083391506"},{"key":"2874_CR21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.parkreldis.2004.10.012","volume":"11","author":"S Przedborski","year":"2005","unstructured":"Przedborski S. Pathogenesis of nigral cell death in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2005;11:S3\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"2874_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Schwarzschild MA. The epidemiology of Parkinson\u2019s disease: risk factors and prevention. The Lancet Neurology. 2016;15(12):1257\u201372.","journal-title":"The Lancet Neurology"},{"key":"2874_CR23","first-page":"101","volume-title":"Purines in Parkinson\u2019s: Adenosine A 2A receptors and urate as targets for neuroprotection","author":"R Bakshi","year":"2015","unstructured":"Bakshi R, Logan R, Schwarzschild MA. Purines in Parkinson\u2019s: Adenosine A 2A receptors and urate as targets for neuroprotection. The Adenosinergic System: Springer; 2015. p. 101\u201326."},{"key":"2874_CR24","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1002\/mds.26476","volume":"31","author":"IH Fernandez","year":"2016","unstructured":"Fernandez IH, Jesus S, Lojo JA, Gomez FJG, Redondo MC, Ruiz JMO, et al. Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson\u2019s disease subtype. Mov Disord. 2016;31:S250\u20131.","journal-title":"Mov Disord"},{"issue":"2","key":"2874_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","volume":"71","author":"MA Schwarzschild","year":"2014","unstructured":"Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141\u201350.","journal-title":"JAMA Neurol"},{"issue":"4","key":"2874_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ana.25436","volume":"85","author":"R Bakshi","year":"2019","unstructured":"Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019;85(4):593\u20139.","journal-title":"Ann Neurol"},{"key":"2874_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"9","key":"2874_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"2874_CR29","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JP, Altman DG, Group obotCSM. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. 2019. p. 241\u201384.","DOI":"10.1002\/9781119536604.ch10"},{"issue":"7414","key":"2874_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"9","key":"2874_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0895-4356(02)00443-2","volume":"55","author":"M Symons","year":"2002","unstructured":"Symons M, Moore D. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol. 2002;55(9):893\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"2874_CR32","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Kai FY. What\u2019s the relative risk?: A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690\u20131.","journal-title":"JAMA"},{"key":"2874_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"issue":"7109","key":"2874_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"key":"2874_CR35","first-page":"548","volume":"49","author":"J Liu","year":"2016","unstructured":"Liu J, Dan X, Zhang H, Chan P. Serum uric acid and lifestyle factors associated with the risk of Parkinson\u2019s disease. 2016;49:548\u201352.","journal-title":"Serum uric acid and lifestyle factors associated with the risk of Parkinson's disease"},{"issue":"17","key":"2874_CR36","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1212\/01.wnl.0000279518.10072.df","volume":"69","author":"A Alonso","year":"2007","unstructured":"Alonso A, Garcia Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease - A prospective study. Neurology. 2007;69(17):1696\u2013700.","journal-title":"Neurology"},{"issue":"11","key":"2874_CR37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.24193","volume":"59","author":"M De Vera","year":"2008","unstructured":"De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson\u2019s disease: a cohort study. Arthritis Rheum. 2008;59(11):1549\u201354.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2874_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10654-013-9791-1","volume":"28","author":"E Schernhammer","year":"2013","unstructured":"Schernhammer E, Qiu JH, Wermuth L, Lassen CF, Friis S, Ritz B. Gout and the risk of Parkinson\u2019s disease in Denmark. Eur J Epidemiol. 2013;28(4):359\u201360.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"2874_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijge.2013.01.006","volume":"8","author":"SW Lai","year":"2014","unstructured":"Lai SW, Lin CH, Lin CL, Liao KF. Gout and Parkinson\u2019s Disease in Older People: An Observation in Taiwan. Int J Gerontol. 2014;8(3):166\u20137.","journal-title":"Int J Gerontol"},{"key":"2874_CR40","doi-asserted-by":"crossref","unstructured":"Pakpoor J, Seminog OO, Ramagopalan SV, Pakpoor J, Seminog Goldacre MJ. Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. BMC Neurol. 2015;15:16.","DOI":"10.1186\/s12883-015-0273-9"},{"key":"2874_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.parkreldis.2018.03.026","volume":"52","author":"M Cortese","year":"2018","unstructured":"Cortese M, Riise T, Engeland A, Ascherio A, Bj\u00f8rnevik K. Urate and the risk of Parkinson\u2019s disease in men and women. Parkinsonism Relat Disord. 2018;52:76\u201382.","journal-title":"Parkinsonism Relat Disord"},{"key":"2874_CR42","doi-asserted-by":"crossref","unstructured":"Singh JA, Cleveland JD. Gout and the risk of Parkinson's disease in older adults: a study of U.S. Medicare data. BMC Neurol. 2019;19(1):4.","DOI":"10.1186\/s12883-018-1234-x"},{"issue":"1","key":"2874_CR43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12883-020-01916-9","volume":"20","author":"LY Hu","year":"2020","unstructured":"Hu LY, Yang AC, Lee SC, You ZH, Tsai SJ, Hu CK, et al. Risk of Parkinson\u2019s disease following gout: a population-based retrospective cohort study in Taiwan. BMC Neurol. 2020;20(1):338.","journal-title":"BMC Neurol"},{"issue":"12","key":"2874_CR44","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/medicina57121292","volume":"57","author":"JH Kim","year":"2021","unstructured":"Kim JH, Choi IA, Kim A, Kang G. Clinical Association between Gout and Parkinson\u2019s Disease: A Nationwide Population-Based Cohort Study in Korea. Medicina (Kaunas). 2021;57(12):1292.","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"2874_CR45","doi-asserted-by":"publisher","first-page":"105402","DOI":"10.1016\/j.jbspin.2022.105402","volume":"89","author":"MA Pou","year":"2022","unstructured":"Pou MA, Orfila F, Pagonabarraga J, Ferrer-Moret S, Corominas H, Diaz-Torne C. Risk of Parkinson\u2019s disease in a gout Mediterranean population: A case-control study. Joint Bone Spine. 2022;89(6):105402.","journal-title":"Joint Bone Spine"},{"issue":"10","key":"2874_CR46","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.parkreldis.2015.08.030","volume":"21","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21(10):1238\u201342.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2874_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173731","volume":"12","author":"M Wen","year":"2017","unstructured":"Wen M, Zhou B, Chen Y-H, Ma Z-L, Gou Y, Zhang C-L, et al. Serum uric acid levels in patients with Parkinson\u2019s disease: A meta-analysis. PLoS ONE. 2017;12(3):e0173731.","journal-title":"PLoS ONE"},{"issue":"9","key":"2874_CR48","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/aje\/kwp033","volume":"169","author":"H Chen","year":"2009","unstructured":"Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson\u2019s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169(9):1064\u20139.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2874_CR49","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1471-4159.1998.70010268.x","volume":"70","author":"E Floor","year":"1998","unstructured":"Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem. 1998;70(1):268\u201375.","journal-title":"J Neurochem"},{"issue":"45","key":"2874_CR50","doi-asserted-by":"publisher","first-page":"e8502-e","DOI":"10.1097\/MD.0000000000008502","volume":"96","author":"Z Yu","year":"2017","unstructured":"Yu Z, Zhang S, Wang D, Fan M, Gao F, Sun W, et al. The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review. Medicine (Baltimore). 2017;96(45):e8502-e.","journal-title":"Medicine (Baltimore)"},{"key":"2874_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fnana.2015.00091","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front Neuroanat. 2015;9:91.","journal-title":"Front Neuroanat"},{"key":"2874_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fnmol.2018.00021","volume":"11","author":"M Bi","year":"2018","unstructured":"Bi M, Jiao Q, Du X, Jiang H. Glut9-mediated urate uptake is responsible for its protective effects on dopaminergic neurons in Parkinson\u2019s disease models. Front Mol Neurosci. 2018;11:21.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"2874_CR53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-2010-1330","volume":"19","author":"GL Bowman","year":"2010","unstructured":"Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19(4):1331\u20136.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2874_CR54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1073\/pnas.1217296110","volume":"110","author":"X Chen","year":"2013","unstructured":"Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci. 2013;110(1):300\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2874_CR55","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.bbrc.2017.10.004","volume":"493","author":"T-T Huang","year":"2017","unstructured":"Huang T-T, Hao D-L, Wu B-N, Mao L-L, Zhang J. Uric acid demonstrates neuroprotective effect on Parkinson\u2019s disease mice through Nrf2-ARE signaling pathway. Biochem Biophys Res Commun. 2017;493(4):1443\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 2","key":"2874_CR56","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1136\/annrheumdis-2014-eular.5933","volume":"73","author":"T Khalfina","year":"2014","unstructured":"Khalfina T, Maksudova A. AB0849 Oxidative Stress, Anti-Oxidant Activity in Patients with Gout. Ann Rheum Dis. 2014;73(Suppl 2):1083.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2874_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/rheumatology\/kes211","volume":"52","author":"LK Stamp","year":"2013","unstructured":"Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013;52(1):34\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2874_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5049\/EBP.2014.12.1.1","volume":"12","author":"D-H Kang","year":"2014","unstructured":"Kang D-H, Ha S-K. Uric acid puzzle: dual role as anti-oxidantand pro-oxidant. Electrolytes & Blood Pressure. 2014;12(1):1\u20136.","journal-title":"Electrolytes & Blood Pressure"},{"issue":"32","key":"2874_CR59","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.2174\/138161205774913255","volume":"11","author":"G Glantzounis","year":"2005","unstructured":"Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145\u201351.","journal-title":"Curr Pharm Des"},{"key":"2874_CR60","doi-asserted-by":"publisher","first-page":"828476","DOI":"10.3389\/fpsyt.2022.828476","volume":"13","author":"NR Mijailovic","year":"2022","unstructured":"Mijailovic NR, Vesic K, Borovcanin MM. The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction. Front Psychiatry. 2022;13:828476.","journal-title":"Front Psychiatry"},{"issue":"2","key":"2874_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-020-01757-0","volume":"17","author":"ZW Reavis","year":"2021","unstructured":"Reavis ZW, Mirjankar N, Sarangi S, Boyle SH, Kuhn CM, Matson WR, et al. Sex and race differences of cerebrospinal fluid metabolites in healthy individuals. Metabolomics. 2021;17(2):1\u201313.","journal-title":"Metabolomics"},{"issue":"1","key":"2874_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-86962-0","volume":"11","author":"M Kurajoh","year":"2021","unstructured":"Kurajoh M, Fukumoto S, Yoshida S, Akari S, Murase T, Nakamura T, et al. Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry. Sci Rep. 2021;11(1):1\u20139.","journal-title":"Sci Rep"},{"issue":"11","key":"2874_CR63","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119\u201329.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02874-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02874-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02874-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T16:04:49Z","timestamp":1665504289000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02874-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2874"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02874-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflict of interest declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}